Patients on chronic hemodialysis have no intrinsic lymphocyte defect upon stimulation with interleukin-2, interleukin-15 or tumor necrosis factor-alpha

Blood Purification

Volumn 21, Issue 2, 2003, Pages 158-162

  Van Riemsdijk, I C ^a   Baan, C C ^a   Loonen, E H M ^a   Zietse, R ^a   Weimar, W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Hemodialysis; Interleukin 15; Interleukin 2; Lymphocyte proliferation; Tumor necrosis factor

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 2; RECOMBINANT CYTOKINE; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIGEN PRESENTING CELL; ARTICLE; CELL COUNT; CELL ISOLATION; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; LYMPHOCYTE PROLIFERATION; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL;

CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HUMANS; IMMUNOCOMPETENCE; INTERLEUKIN-15; INTERLEUKIN-2; KIDNEY FAILURE, CHRONIC; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RENAL DIALYSIS; T-LYMPHOCYTE SUBSETS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037219682     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069154     Document Type: Article

References (31)

1. Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, Alleyne S, et al: Immunologic function and survival in hemodialysis patients. Kidney Int 1998;54:236-244.
2. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lownfels AB, et al: Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999;354:93-99.
3. Male D, Roitt I: Introduction to the immune system; in Roitt I, Brostoff J, Male D (eds): Immunology, ed 5. St. Louis, Mosby, 1998, pp 1-11.
4. Feldmann M: Cell cooperation in the antibody response; in Roitt J, Brostoff J, Male DK (eds): Immunology, ed 5. St Louis, Mosby, 1998, chapt 11, pp 139-159.
5. Weiler M, Rogashev B, Einbinder T, Hausmann MJ, Kaneti J, Chaimovitz C, et al: Interleukin-15, a leukocyte activator and growth factor, is produced by cortical tubular epithelial cells. J Am Soc Nephrol 1998;9:1194-1201.
6. Baan CC, Knoop CJ, Holweg CT, van Gelder T, Metselaar HJ, Niesters HG, et al: The macrophage-derived T-cell growth factor interleukin-15 is present in interleukin-2-indepenent rejection after clinical heart and liver transplantation. Transplant Proc 1999;31:2726-2728.
7. Kennedy MK, Park LS: Characterization of interleukin-15 (IL-15) and the IL-15 receptor complex. J Clin Immunol 1996;16:134-143.
8. McInnes IB, Liew FY: Interleukin 15: A proinflammatory role in rheumatoid arthritis synovitis. Immunol Today 1998;19:75-79.
9. Girndt M, Sester U, Sester M, Kaul H, Kohler H: Impaired cellular immune function in patients with end-stage renal failure. Nephrol Dial Transplant 1999;14:2807-2810.
10. Chatenoud L, Dugas B, Beaurain G, Touam M, Drueke T, Vasquez A, et al: Presence of preactivated T cells in hemodialyzed patients: Their possible role in alteed immunity. Proc Natl Acad Sci USA 1986;83:7457-7461.
11. Girndt M, Kohler H, Schiedhelm-Weick E, Schlaak JF, Meyer zum Buschenfelde K, Fleischer B: Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int 1995;47:559-565.
12. Girndt M, Kohler H, Schiedhelm-Weick E, Meyer zum Buschenfelde K, Fleischer B: T cell activation defect in hemodialysis patients: evidence for a role of the B7/CD28 pathway. Kidney Int 1993;44:359-365.
13. Donati D, Degiannis D, Raskova J, Raska KJ: Uremic serum effects on peripheral blood mononuclear cell and purified T lymphocyte responses. Kidney Int 1992;42:681-689.
14. Lonnemann G, Haubitz M, Schindler R: Hemodialysis-associated induction of cytokines. Blood Purif 1990;8:214-222.
15. Zaoui P, Green W, Hakim RM: Hemodialysis with cuprophane membrane modulates interleukin-2 receptor expression. Kidney Int 1991;39:1020-1026.
16. Roccatello D, D'Alfonso S, Peruccio D, Quattrocchio G, Cavalli G, Isidoro C, et al: Induction of mRNA for tumor necrosis factor alpha in hemodialysis. Kidney Int Suppl 1993;39:S144-S148.
17. Pereira BJ, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA: Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 1994;45:890-896.
18. Engelberts I, Francot GJ, Leunissen KM, Haenen B, Ceska M, van der Linden CJ, et al: Effect of hemodialysis on peripheral blood monocyte tumor necrosis factor-alpha, interleukin-6, and interleukin-8 secretion in vitro. Nephron 1994;66:396-403.
19. Descamps-Latscha B, Herbelin A, Nguyen AT, Roux-Lombard P, Zingraff J, Moynot A, et al: Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. J Immunol 1995;154:882-892.
20. Pereira BJ: Balance between pro-inflammatory cytokines and their specific inhibitors in patients on dialysis. Nephrol Dial Transplant 1995;10(suppl 7):27-32.
21. Lin YF, Chang DM, Shaio MF, Lu KC, Chyr SH, Li BL, et al: Cytokine production during hemodialysis: Effects of dialytic membrane and complement activation. Am J Nephrol 1996;16:293-299.
22. Kelley CJ: T cell function in chronic renal failure and dialysis. Blood Purif 1994;12:36-41.
23. Modai D, Berman S, Sheleg Y, Cohn M, Weissgarten J, Averbukh Z: Interleukin-2 receptor is similarly expressed by activated lymphocytes from patients on chronic hemodialysis and healthy subjects. Clin Immunol Immunopathol 1990;55:237-241.
24. Kurz P, Kohler H, Meuer S, Hutteroth T, Meyer zum Buschenfelde KH: Impaired cellular immune responses in chronic renal failure: evidence for a T cell defect. Kidney Int 1986; 29:1209-1214.
25. van Riemsdijk IC, Baan CC, Loonen EH, Knoop CJ, Navarro BG, Niesters HG, et al: T cells activate the tumor necrosis factor-alpha system during hemodialysis, resulting in tachyphylaxis. Kidney Int 2001;59:883-892.
26. van Riemsdijk IC, Baan CC, Knoop CJ, Loonen EH, Zietse R, Weimar W: Quantitative flow cytometry shows activation of the TNF-alpha system but not of the IL-2 system at the single cell level in renal replacement therapy. Nephrol Dial Transplant 2001;16:1430-1435.
27. Le Meur Y, Lorgeot V, Aldigier JC, Wijdenes J, Leroux-Robert C, Praloran V: Whole blood production of monocytic cytokines (IL-1beta, IL-6, TNF-alpha, sIL-6R, IL-1Ra) in haemodialysed patients. Nephrol Dial Transplant 1999;14:2420-2426.
28. Descamps-Latscha B, Herbelin A, Nguyen AT, Zingraff J, Jungers P, Chatenoud L: Immune system dysregulation in uremia. Semin Nephrol 1994;14:253-260.
29. Deenitchina SS, Ando T, Okuda S, Kinukawa N, Hirakata H, Nagashima A, et al: Cellular immunity in hemodialysis patients: A quantitative analysis of immune cell subsets by flow cytometry. Am J Nephrol 1995;15:57-65.
30. Zamauskaite A, Perez-Cruz I, Yaqoob MM, Madrigal JA, Cohen SB: Effect of renal dialysis therapy modality on T cell cytokine production. Nephrol Dial Transplant 1999;14:49-55.
31. Girndt M, Sester U, Kaul H, Kohler H: Production of proinflammatory and regulatory monokines in hemodialysis patients shown at a single-cell level. J Am Soc Nephrol 1998;9:1689-1696.